Literature DB >> 12938095

Molecular analysis in Fabry disease in Spain: fifteen novel GLA mutations and identification of a homozygous female.

Adriana Rodríguez-Marí1, M José Coll, Amparo Chabás.   

Abstract

Fabry disease, an X-linked inborn error of glycosphingolipid catabolism, results from mutations in the alpha-galactosidase A gene (GLA). Here we report molecular studies in 22 unrelated Spanish patients with Fabry disease ( 20 males and two females). Fifteen novel mutations were identified. In addition 7 previously described mutations and two previously reported polymorphisms were detected. The 15 novel mutations comprise: eight missense E48K (c.142G>A), W81S (c.242G>C), D170H (c.508G>C), W226C (c.678G>T), Q279R (c.836A>G), C382Y (c.1145G>A), I407K (c.1220T>A), L414S (c.1241T>C); one nonsense W95X (c.284G>A); one insertion Y216fsX15 (c.646_647insT); two small deletions G346fsX1 (c.1037delG), K426fsX23 (c.1277_1278delAA); one gross deletion comprising exons 5, 6, 7; one complex mutation (insertion and deletion) A368fsX24 (c.1102delGinsTTATAC), and one splice-site mutation IVS4+1G>A (c.639+1G>A). One of the females was found homozygous for Q279R mutation and she presented with the classic phenotype since the age of 8 years, this case extending into women the severe phenotype observed in classically affected males. Mutation analysis provided precise identification for 30 heterozygotes among female relatives and detection of a de novo mutation. The molecular studies on Spanish Fabry patients here reported further contribute to the identification of new mutations in this disease, and allow reliable detection of heterozygotes which has consequences for genetic counselling and for treatment. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12938095     DOI: 10.1002/humu.9172

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  22 in total

1.  Functional analysis of variant lysosomal acid glycosidases of Anderson-Fabry and Pompe disease in a human embryonic kidney epithelial cell line (HEK 293 T).

Authors:  Hatim Y Ebrahim; Robert J Baker; Atul B Mehta; Derralynn A Hughes
Journal:  J Inherit Metab Dis       Date:  2011-10-05       Impact factor: 4.982

2.  The alpha-galactosidase A p.Arg118Cys variant does not cause a Fabry disease phenotype: data from individual patients and family studies.

Authors:  Susana Ferreira; Alberto Ortiz; Dominique P Germain; Miguel Viana-Baptista; António Caldeira-Gomes; Marta Camprecios; Maria Fenollar-Cortés; Ángel Gallegos-Villalobos; Diego Garcia; José Antonio García-Robles; Jesús Egido; Eduardo Gutiérrez-Rivas; José Antonio Herrero; Sebastián Mas; Raluca Oancea; Paloma Péres; Luis Manuel Salazar-Martín; Jesús Solera-Garcia; Helena Alves; Scott C Garman; João Paulo Oliveira
Journal:  Mol Genet Metab       Date:  2014-11-09       Impact factor: 4.797

3.  Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey).

Authors:  B Hoffmann; A Garcia de Lorenzo; A Mehta; M Beck; U Widmer; R Ricci
Journal:  J Med Genet       Date:  2005-03       Impact factor: 6.318

4.  Structure-function relationships in alpha-galactosidase A.

Authors:  Scott C Garman
Journal:  Acta Paediatr       Date:  2007-04       Impact factor: 2.299

Review 5.  Fabry's disease: an example of cardiorenal syndrome type 5.

Authors:  Aashish Sharma; Marco Sartori; Jose J Zaragoza; Gianluca Villa; Renhua Lu; Elena Faggiana; Alessandra Brocca; Luca Di Lullo; Sandro Feriozzi; Claudio Ronco
Journal:  Heart Fail Rev       Date:  2015-11       Impact factor: 4.214

6.  Structural characterization of mutant alpha-galactosidases causing Fabry disease.

Authors:  Kanako Sugawara; Kazuki Ohno; Seiji Saito; Hitoshi Sakuraba
Journal:  J Hum Genet       Date:  2008-07-17       Impact factor: 3.172

7.  Identification of Cryptic Novel α-Galactosidase A Gene Mutations: Abnormal mRNA Splicing and Large Deletions.

Authors:  Takashi Higuchi; Masahisa Kobayashi; Jin Ogata; Eiko Kaneshiro; Yohta Shimada; Hiroshi Kobayashi; Yoshikatsu Eto; Shiro Maeda; Akira Ohtake; Hiroyuki Ida; Toya Ohashi
Journal:  JIMD Rep       Date:  2016-06-03

Review 8.  Progress in the understanding and treatment of Fabry disease.

Authors:  James J Miller; Adam J Kanack; Nancy M Dahms
Journal:  Biochim Biophys Acta Gen Subj       Date:  2019-09-14       Impact factor: 3.770

9.  A classical phenotype of Anderson-Fabry disease in a female patient with intronic mutations of the GLA gene: a case report.

Authors:  Antonio Pisani; Massimo Imbriaco; Carmela Zizzo; Giuseppe Albeggiani; Paolo Colomba; Riccardo Alessandro; Francesco Iemolo; Giovanni Duro
Journal:  BMC Cardiovasc Disord       Date:  2012-06-08       Impact factor: 2.298

10.  Serum globotriaosylceramide assay as a screening test for fabry disease in patients with ESRD on maintenance dialysis in Korea.

Authors:  Jeong-Yup Kim; Young-Youl Hyun; Ji-Eun Lee; Hye-Ran Yoon; Gu-Hwan Kim; Han-Wook Yoo; Seong-Tae Cho; No-Won Chun; Byoung-Chunn Jeoung; Hwa-Jung Kim; Keong-Wook Kim; Seong-Nam Kim; Yung-A Kim; Hyun-Ah Lee; Jong-Young Lee; Yung-Chun Lee; Hun-Kwan Lim; Keong-Sik Oh; Seong-Hwan Son; Beong-Hee Yu; Kyeong-So Wee; Eun-Jong Lee; Young-Ki Lee; Jung-Woo Noh; Seung-Jung Kim; Kyu-Bok Choi; Suk-Hee Yu; Heui-Jung Pyo; Young-Joo Kwon
Journal:  Korean J Intern Med       Date:  2010-11-27       Impact factor: 3.165

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.